{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=44", "query": { "intervention": "Matching Oral Placebo", "page": 44 }, "page_size": 10 }, "pagination": { "page": 44, "page_size": 10, "total_count": 3459, "total_pages": 346, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=45&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Oral+Placebo&page=43&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T23:38:23.360Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02830932", "title": "Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Respiratory Syncytial Virus (RSV)" ], "interventions": [ { "name": "VXA-RSV-f Tablets (high dose)", "type": "BIOLOGICAL" }, { "name": "VXA Placebo Tablets", "type": "OTHER" }, { "name": "VXA-RSV-f Tablets (low dose)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Vaxart", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 66, "start_date": "2016-06-22", "completion_date": "2017-09-20", "has_results": false, "last_update_posted_date": "2018-08-16", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 1, "location_summary": "Melbourne, Florida", "locations": [ { "city": "Melbourne", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02830932" }, { "nct_id": "NCT01641809", "title": "Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1265744 10 mg", "type": "DRUG" }, { "name": "GSK1265744 30 mg", "type": "DRUG" }, { "name": "GSK1265744 60 mg", "type": "DRUG" }, { "name": "Efavirenz 600 mg", "type": "DRUG" }, { "name": "Rilpivirine 25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2012-08-06", "completion_date": "2019-01-15", "has_results": true, "last_update_posted_date": "2020-01-30", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01641809" }, { "nct_id": "NCT00810693", "title": "A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pulmonary Hypertension" ], "interventions": [ { "name": "Riociguat (Adempas, BAY63-2521)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 445, "start_date": "2008-12-17", "completion_date": "2012-05-14", "has_results": true, "last_update_posted_date": "2023-11-22", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 18, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00810693" }, { "nct_id": "NCT05135000", "title": "Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension" ], "interventions": [ { "name": "LTP001", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 47, "start_date": "2022-06-30", "completion_date": "2024-04-25", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 2, "location_summary": "Mesa, Arizona • Charleston, South Carolina", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05135000" }, { "nct_id": "NCT00631007", "title": "A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "INT131 besylate", "type": "DRUG" }, { "name": "Pioglitazone HCl", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "InteKrin Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "30 Years to 75 Years" }, "enrollment_count": 367, "start_date": "2008-02", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2010-09-13", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 59, "location_summary": "Carmichael, California • Los Angeles, California • San Diego, California + 48 more", "locations": [ { "city": "Carmichael", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00631007" }, { "nct_id": "NCT04480736", "title": "A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "JNJ-64281802 High dose", "type": "DRUG" }, { "name": "JNJ-64281802 Medium dose", "type": "DRUG" }, { "name": "JNJ-64281802 Low dose", "type": "DRUG" }, { "name": "JNJ-64281802 Dosing Regimen X", "type": "DRUG" }, { "name": "JNJ-64281802 Dosing Regimen Y", "type": "DRUG" }, { "name": "JNJ-64281802 Dosing Regimen Z", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2020-07-28", "completion_date": "2027-12-09", "has_results": false, "last_update_posted_date": "2025-01-10", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 1, "location_summary": "Syracuse, New York", "locations": [ { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04480736" }, { "nct_id": "NCT06963021", "title": "NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "NBI-1065845", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurocrine Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2025-05-30", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 15, "location_summary": "Chino, California • Los Angeles, California • Stanford, California + 11 more", "locations": [ { "city": "Chino", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Cromwell", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06963021" }, { "nct_id": "NCT01241214", "title": "Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Seasonal Allergic Rhinitis" ], "interventions": [ { "name": "ACT-129968", "type": "DRUG" }, { "name": "Cetirizine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Idorsia Pharmaceuticals Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 579, "start_date": "2010-11", "completion_date": "2011-02", "has_results": false, "last_update_posted_date": "2019-05-15", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 7, "location_summary": "Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Kerrville", "state": "Texas" }, { "city": "New Braunfels", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01241214" }, { "nct_id": "NCT03257865", "title": "A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bipolar I Disorder", "Manic Episode" ], "interventions": [ { "name": "Brexpiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 333, "start_date": "2017-09-19", "completion_date": "2019-01-22", "has_results": true, "last_update_posted_date": "2020-02-11", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 27, "location_summary": "Little Rock, Arkansas • Bellflower, California • Cerritos, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257865" }, { "nct_id": "NCT00460707", "title": "A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nausea and Vomiting, Chemotherapy-Induced" ], "interventions": [ { "name": "Casopitant 150 mg", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Casopitant 150 mg matching placebo", "type": "DRUG" }, { "name": "Casopitant 50 mg", "type": "DRUG" }, { "name": "Casopitant 50 mg matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 85, "start_date": "2007-04-16", "completion_date": "2007-08-27", "has_results": false, "last_update_posted_date": "2017-08-03", "last_synced_at": "2026-10-16T23:38:23.360Z", "location_count": 3, "location_summary": "Overland Park, Kansas • Buffalo, New York • Columbus, Ohio", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Buffalo", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00460707" } ] }